Pathogenesis and treatment of renal osteodystrophy.
Renal osteodystrophy is the term used to describe the many different patterns of the skeletal abnormalities that occur in patients with chronic kidney disease. The main two conditions are osteitis fibrosa, characterized by high bone turnover, increased osteoclastic and osteoblastic activity, and high levels of circulating parathyroid hormone (PTH) and adynamic bone disease characterized by low bone turnover and low levels of circulating PTH. Retention of phosphorus, decreased levels of calcitriol in blood, decreased levels of serum ionized calcium, reduced numbers of vitamin D receptors and calcium sensors in the parathyroid gland, and skeletal resistance to the calcemic action of PTH play a major role in the development of renal osteodystrophy. This review will describe the current approach for the treatment of renal osteodystrophy.
Slatopolsky
Eduardo
E
Renal Division, Washington University School of Medicine, St. Louis, MO 63110, USA. eslatopo@im.wustl.edu
Gonzalez
Esther
E
Martin
Kevin
K
D002117:Calcitriol / Q000008:administration & dosage / Q000096:biosynthesis; D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016105:Parathyroidectomy; D010758:Phosphorus / Q000008:administration & dosage / Q000378:metabolism
D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium